Travere Therapeutics Inc Revenue Growth Rates (TVTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Travere Therapeutics Inc   (NASDAQ: TVTX)
 

TVTX's Revenue Growth by Quarter and Year

Travere Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TVTX/growth
https://api.csimarket.com/api/v1/companies/TVTX/fundamentals
https://api.csimarket.com/api/v1/companies/TVTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TVTX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 224.56
2nd Quarter June 169.58
1st Quarter March 127.20
FY 521.34

TVTXs Annual Revenue
Travere Therapeutics Inc 's Revenue in the fiscal year 2025 $ 490.73 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2024 $ 233.18 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2023 $ 145.24 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2022 $ 212.02 millions
Travere Therapeutics Inc 's Revenue in the fiscal year 2021 $ 227.49 millions




TVTX Revenue third quarter 2026 Y/Y Growth Comment
Travere Therapeutics Inc reported Revenue improvement of 36.21% year on year in the third quarter 2026, to $ 224.56 millions, this is lower than Travere Therapeutics Inc 's recent average Revenue surge of 1387.27%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Revenue growth. While Travere Therapeutics Inc ' s Revenue rise of 36.21% ranks overall at the positon no. 486 in the third quarter 2026.


TVTX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 36.21 %
2nd Quarter June 48.17 %
1st Quarter March 55.63 %
FY   -

Financial Statements
Travere Therapeutics Inc 's third quarter 2026 Revenue $ 224.56 millions TVTX's Income Statement
Travere Therapeutics Inc 's third quarter 2025 Revenue $ 164.86 millions Quarterly TVTX's Income Statement


TVTX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 32.42 %
2nd Quarter June 33.32 %
1st Quarter March -1.92 %
FY (Year on Year)   -


Back to TVTX Growth rate Comparisons >> Back to TVTX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #120
Overall #486

Revenue Y/Y Growth Statistics
High Average Low
62164.52 % 1387.27 % -30.66 %
(Dec 31 2015)   (Jun 30 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #120
Overall #486
Revenue Y/Y Growth Statistics
High Average Low
62164.52 % 1387.27 % -30.66 %
(Dec 31 2015)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Travere Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
20479.69 % 426.66 % -37.86 %
(Jun 30 2014)  


TVTX's III. Quarter Q/Q Revenue Comment
Travere Therapeutics Inc achieved in the III. Quarter 2026 below company average Revenue jump of 32.42% quarter on quarter, to $ 224.56 millions.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Travere Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 336.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #79
Overall #336
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #79
Overall #336
Revenue Q/Q Growth Statistics
High Average Low
20479.69 % 426.66 % -37.86 %
(Jun 30 2014)  


TVTX's III. Quarter Q/Q Revenue Comment
Travere Therapeutics Inc achieved in the III. Quarter 2026 below company average Revenue jump of 32.42% quarter on quarter, to $ 224.56 millions.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Travere Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 336.


Travere Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 651.03
Y / Y Revenue Growth (TTM) 49.38 %
Year on Year Revenue Growth Overall Ranking # 177
Seqeuential Revenue Change (TTM) 10.1 %
Seq. Revenue Growth (TTM) Overall Ranking # 774


Cumulative Revenue growth Comment
Assuming the Travere Therapeutics Inc 's fiscal year would have ended in Sep 30 2026, Travere Therapeutics Inc would have reprted above average annual Revenue growth of 49.38% year on year, of $ 651 millions.
This marks a slow-down of the companys growth trends and from the 77.12% increase in Jun 30 2026.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 177.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 51
Overall # 177

Revenue TTM Y/Y Growth Statistics
High Average Low
254.19 %
 30.76 %
-21.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 161
S&P 500 # 774
Cumulative Revenue growth Comment
Assuming the Travere Therapeutics Inc 's fiscal year would have ended in Sep 30 2026, Travere Therapeutics Inc would have reprted above average annual Revenue growth of 49.38% year on year, of $ 651 millions.
This marks a slow-down of the companys growth trends and from the 77.12% increase in Jun 30 2026.

In the Healthcare sector 50 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 177.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 51
Overall # 177

Revenue TTM Y/Y Growth Statistics
High Average Low
254.19 %
30.76 %
-21.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 161
S&P 500 # 774




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TVTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions


About Travere Therapeutics Inc Revenue Growth Rates (TVTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Travere Therapeutics Inc (CIK 1438533).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001438533-26-000077
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Travere Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.